• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep Med . Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection

tetano

Editor, Senior Moderator
Cell Rep Med


. 2022 Sep 19;100764.
doi: 10.1016/j.xcrm.2022.100764. Online ahead of print.
Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection


Hye Won Jeong[SUP] 1 [/SUP], Se-Mi Kim[SUP] 2 [/SUP], Min Kyung Jung[SUP] 3 [/SUP], Ji Yun Noh[SUP] 4 [/SUP], Ji-Seung Yoo[SUP] 2 [/SUP], Eun-Ha Kim[SUP] 5 [/SUP], Young-Il Kim[SUP] 2 [/SUP], Kwangmin Yu[SUP] 5 [/SUP], Seung-Gyu Jang[SUP] 6 [/SUP], Juryeon Gil[SUP] 5 [/SUP], Mark Anthony Casel[SUP] 6 [/SUP], Rollon Rare[SUP] 6 [/SUP], Jeong Ho Choi[SUP] 5 [/SUP], Hee-Sung Kim[SUP] 1 [/SUP], Jun Hyoung Kim[SUP] 7 [/SUP], Jihye Um[SUP] 8 [/SUP], Chaeyoon Kim[SUP] 3 [/SUP], Yeonjae Kim[SUP] 9 [/SUP], Bum Sik Chin[SUP] 9 [/SUP], Sungmin Jung[SUP] 10 [/SUP], Jun Yong Choi[SUP] 11 [/SUP], Kyoung-Ho Song[SUP] 12 [/SUP], Yong-Dae Kim[SUP] 13 [/SUP], Jun-Sun Park[SUP] 8 [/SUP], Joon Young Song[SUP] 14 [/SUP], Eui-Cheol Shin[SUP] 15 [/SUP], Young Ki Choi[SUP] 16 [/SUP]



Affiliations
Free article

Abstract

Omicron has become the globally dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade neutralization. Here, we report that neutralizing antibodies against Omicron variants are undetected following COVID-19 infection with ancestral or past SARS-CoV-2 variant viruses or after two-dose mRNA vaccination. Compared with two-dose vaccination, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Intriguingly, among individuals with three-dose vaccination, Omicron breakthrough infection substantially augments serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, after Omicron breakthrough infection, memory T cells respond to the spike proteins of both ancestral and Omicron SARS-CoV-2 by producing cytokines with polyfunctionality. These results suggest that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern.

Keywords: D614G; Omicron BA.1; Omicron BA.2; SARS-CoV-2; T cell immune response; ancestral; breakthrough infection; cross-neutralization; mRNA vaccine; recovered patient; variants of concern.
 
Back
Top Bottom